SEASONALE bulk active fine chemical vendors

Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
ABI Chem	⤷ Start Trial	AC1L2NM9	⤷ Start Trial
J&H Chemical Co.,ltd	⤷ Start Trial	JH285923	⤷ Start Trial
RR Scientific	⤷ Start Trial	R207957	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 29, 2025

Introduction

SEASONALE is an oral contraceptive extensively prescribed for birth control and menstrual regulation. Its primary active pharmaceutical ingredient (API) is ethinylestradiol (EE) and levonorgestrel. As manufacturers and healthcare providers rely on consistent, high-quality APIs, understanding the sources, supply chain, and regulatory landscape of these APIs becomes imperative. This article provides a comprehensive overview of bulk API sources for SEASONALE, emphasizing the industry landscape, manufacturing, quality standards, and strategic considerations for stakeholders.

Understanding the APIs in SEASONALE

Ethinylestradiol (EE): A synthetic estrogen, it serves as the estrogen component in hormonal contraceptives, including SEASONALE. Its potency, stability, and bioavailability make it a key ingredient.

Levonorgestrel: A synthetic progestogen utilized for its ovulation inhibition and endometrial effects, contributing to contraceptive efficacy.

Both APIs require strict quality control, and their sourcing significantly impacts drug safety, efficacy, regulatory compliance, and market stability.

Global API Manufacturing Landscape

The APIs in SEASONALE are produced predominantly in Asia, Europe, and North America, with Asia accounting for the largest share due to manufacturing cost advantages and established chemical syntheses.

Key API Manufacturing Regions

India: Leading producer of both EE and levonorgestrel, known for large-scale chemical synthesis, cost-effective operations, and robust manufacturing infrastructure aligned with international standards.
China: Significant exporter of APIs, especially in steroid synthesis, with increasing compliance to quality standards via GMP certifications.
Europe: Suppliers here often provide high-purity APIs with advanced quality assurance, typically catering to high-value, regulatory-sensitive markets.
United States: While primarily dependent on imports for active ingredients, several U.S.-based companies produce APIs under stringent regulatory oversight for niche markets.

Leading API Manufacturers for SEASONALE

Ethinylestradiol

Mohana Pharma Limited (India): Known for producing high-quality EE compliant with USP and EP standards. They focus on large-volume bulk supply with stringent quality assurance.
Sichuan Vikang Pharmaceutical Co., Ltd. (China): Offers active pharmaceutical ingredients including EE, with GMP-certified facilities and competitive pricing.
Laboratorios Farmacéuticos ROVI (Spain): Provides high-quality EE with a focus on European and global markets, adhering to international regulatory standards.
Pfizer Inc. (USA): Historically involved in steroid synthesis, their APIs typically meet the highest quality standards, although they may supply through authorized distributors.

Levonorgestrel

Hubei Puluo Pharmaceutical Co., Ltd. (China): Major supplier offering levonorgestrel with comprehensive GMP certifications, suitable for pharmaceutical applications requiring batch-to-batch consistency.
Fannin Ltd. (India): Offers high-purity levonorgestrel, with extensive regulatory approvals aligned with global standards, and a reputation for reliable supply.
Haupt Pharma GmbH & Co. (Germany): Provides premium APIs with rigorous testing and certification, focusing on markets requiring high regulatory compliance.
Mingfeng Pharmaceutical Co., Ltd. (China): Known for competitive pricing and reliable supply chain management for levonorgestrel.

Quality Standards and Regulatory Considerations

Sourcing APIs for hormonal contraceptives like SEASONALE necessitates compliance with international pharmaceutical standards such as:

USP (United States Pharmacopeia)
EP (European Pharmacopoeia)
JP (Japanese Pharmacopoeia)
ICH (International Council for Harmonisation) guidelines

Manufacturers must demonstrate Good Manufacturing Practice (GMP) adherence, batch consistency, purity standards (usually >99%), and stability data. Regulatory bodies like the FDA, EMA, and PMDA extensively evaluate API quality during drug approval processes.

Supply Chain Factors and Risk Management

API sourcing for SEASONALE involves navigating global supply chain complexities, including geopolitical risks, raw material availability, and manufacturing capacity constraints. Strategies for risk mitigation include:

Diversifying suppliers across regions.
Establishing long-term partnerships with certified API producers.
Monitoring regulatory developments affecting manufacturing and export/import rules.
Investing in quality audits and supply chain transparency.

Emerging Trends in API Sourcing

Shift towards synthetic biology: Analyzing future potential of bio-derived APIs for steroids.
Sustainable synthesis processes: Increasing focus on green chemistry to reduce environmental impact.
Localization and regional manufacturing: Driven by geopolitical factors and trade policies, some companies are establishing regional API production hubs.
Enhanced regulatory scrutiny: Continuous evolution of standards necessitates on-going quality assurance.

Strategic Considerations for Pharmaceutical Companies

Partner with certified API manufacturers holding valid GMP certifications.
Prioritize API suppliers with proven track records in consistency and regulatory compliance.
Engage in contract manufacturing organizations (CMOs) that can provide integrated API and formulation services.
Ensure thorough audit and qualification procedures during supplier selection.
Maintain flexibility to switch suppliers or regions in response to market shifts or supply disruptions.

Concluding Remarks

The geopolitics, quality standards, and manufacturing innovations significantly impact the API supply landscape for SEASONALE’s active ingredients. Engaging with reputable, compliant, and diversified API sources is vital to ensuring regulatory registration, market stability, and the consistent delivery of safe, effective contraceptive products. A strategic approach rooted in rigorous quality management and supply chain resilience will foster sustained success in this highly regulated segment.

Key Takeaways

The dominant API sources for SEASONALE are located in India, China, and Europe, offering a range of cost efficiencies and quality options.
Ensuring compliance with GMP and pharmacopeial standards is paramount for API procurement, accommodating strict regulatory landscapes.
Consolidating supplier relationships with reputable manufacturers mitigates risks of supply disruptions and quality lapses.
Evolving trends include a focus on sustainability, regional manufacturing, and bio-based APIs, shaping future supply chain dynamics.
Vertical integration or strategic partnerships in API manufacturing can enhance stability, compliance, and cost-effectiveness.

FAQs

1. What are the major geographic regions supplying APIs for SEASONALE?
Primarily India, China, and Europe, with each offering a balance of cost, compliance, and quality assurance.

2. How do regulatory standards influence API sourcing decisions?
Regulatory compliance (GMP, pharmacopeia standards) ensures APIs meet safety, purity, and potency requirements critical for drug approval and market access.

3. Can API quality vary significantly between suppliers?
Yes, despite standardization, variability in purity, potency, and batch consistency can occur, underscoring the importance of vendor qualification and audits.

4. What risks are associated with API supply chains in hormonal contraceptives?
Potential risks include geopolitical tensions, raw material shortages, regulatory changes, and quality lapses, which can disrupt supply and affect market availability.

5. How is sustainability influencing API manufacturing for hormonal drugs?
Increasingly, manufacturers are adopting green chemistry practices, reducing environmental impact, and exploring bio-based or synthetic biology approaches for API synthesis.

Sources:

[1] "Global API Market Report," IQVIA, 2022.
[2] "Steroid and Hormone API Industry Overview," Global Chemicals Industry Report, 2021.
[3] "Regulatory Standards for APIs," U.S. FDA, 2023.
[4] "Asian API Manufacturing Landscape," Deloitte Insights, 2022.
[5] "Emerging Trends in Pharmaceutical APIs," PharmTech, 2022.

Bulk Pharmaceutical API Sources for SEASONALE